After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open. But are companies actually benefiting from these moves? Check out our latest quarterly infographic to uncover the Q3 story. Was it more […]
Share:
After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open. But are companies actually benefiting from these moves?
Check out our latest quarterly infographic to uncover the Q3 story. Was it more of the same, or were there some surprises?
Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.
